胶质瘤脑脊液蛋白质组现场资源:切除术与解剖位置对生物标志物发现的影响
研究对74例患者的147份脑脊液样本进行适配体蛋白质组学检测,其中71例为2-4级星形细胞瘤或2-3级少突胶质细胞瘤。发现腰椎、蛛网膜下腔与脑室脑脊液蛋白质组存在显著差异,切除术对脑脊液蛋白质组有显著且演变的纵向影响,不同术后时间点出现不同蛋白集。
要点
- 胶质瘤患者腰椎、蛛网膜下腔与脑室脑脊液蛋白质组存在显著差异。
- 切除术对脑脊液蛋白质组有显著且随时间演变的纵向影响。
- 系列颅内脑脊液样本早期即可能用于疾病监测和靶向治疗药效学评估。
核心结论
- 颅内胶质瘤脑脊液蛋白质组是丰富且动态的潜在生物标志物库,可用于评估切除术和其他治疗随时间的效果。
研究设计与样本
- 对74例患者的147份脑脊液样本进行适配体蛋白质组学检测,其中71例为2-4级星形细胞瘤或2-3级少突胶质细胞瘤。
- 包括胶质瘤患者切除术前与术后颅内脑脊液样本,术后早期(1-16天;n=20例患者)或延迟(86-153天;n=11例患者)时间点获取。
- 还获取了配对腰椎与颅内胶质瘤脑脊液样本(n=14例患者)。
主要发现
- 胶质瘤患者腰椎、蛛网膜下腔与脑室脑脊液蛋白质组之间发现显著差异。
- 切除术对脑脊液蛋白质组有显著且演变的纵向影响,术后不同时间点存在不同蛋白集。
- 对系列颅内脑脊液样本的分析提示早期即可能用于疾病监测和评估靶向治疗(如贝伐珠单抗和免疫治疗)的药效学影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However, the impact of key variables to consider in longitudinal CSF samples for monitoring biomarker discovery, including anatomical location and post-surgical changes, remains unknown. METHODS: Aptamer-based proteomics was performed on 147 CSF samples from 74 patients; 71 of whom had grade 2-4 astrocytomas or grade 2-3 oligodendrogliomas. This included pre- versus post-resection intracranial CSF samples obtained at early (1-16 days; n = 20 patients) or delayed (86-153 days; n = 11 patients) time points for patients with glioma. Paired lumbar versus intracranial glioma CSF samples were also obtained (n = 14 patients). RESULTS: Significant differences were identified in the CSF proteome between lumbar, subarachnoid, and ventricular CSF in patients with gliomas. Importantly, we found that resection had a significant, evolving longitudinal impact on the CSF proteome, with distinct sets of proteins present at different time points since resection. Our analysis of serial intracranial CSF samples suggests the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies, such as bevacizumab and immunotherapies. CONCLUSIONS: The intracranial glioma CSF proteome serves as a rich and dynamic reservoir of potential biomarkers that can be used to evaluate the effects of resection and other therapies over time. All data within this study, including detailed individual clinical annotations, are shared as a resource for the neuro-oncology community to collectively address these unanswered questions and further understand glioma biology through CSF proteomics.
引用
- Riviere-Cazaux C, Graser CJ, Warrington AE, et al. A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery. Neuro Oncol. 2025. PMID: 39786485. doi:10.1093/neuonc/noae277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。